The farthest-along candidates are a viral vector vaccine being tested by the University of Oxford and AstraZeneca, a repurposed vaccine, originally developed in the early 1900s for protection against tuberculosis, and a whole-virus vaccine being tested by the state-owned Chinese company Sinopharm.
Laboratories around the world have paused regular work to pursue treatment for COVID-19. While there are still no evidence-based treatments available, scientists are evaluating a variety of options beyond supportive care.
Given the dependence of modern medicine on antimicrobial drugs, and the inevitability of evolution, why is bringing a new antibiotic to market so difficult, and why are so many companies leaving the industry or going bankrupt?
Antimicrobial resistance (AMR) presents a global health crisis, as every day we encounter more infections that cannot be cured with existing antimicrobials. At the same time, the majority of major drug companies have been scaling back or cutting antibiotic research due to development challenges